Literature DB >> 8830780

Dominant-negative effect on adhesion by myelin Po protein truncated in its cytoplasmic domain.

M H Wong1, M T Filbin.   

Abstract

The myelin Po protein is believed to hold myelin together via interactions of both its extracellular and cytoplasmic domains. We have already shown that the extracellular domains of Po can interact in a homophilic manner (Filbin, M.T., F.S. Walsh, B.D. Trapp, J.A. Pizzey, and G.I. Tennekoon. 1990. Nature (Lond.). 344:871-872). In addition, we have shown that for this homophilic adhesion to take place, the cytoplasmic domain of Po must be intact and most likely interacting with the cytoskeleton; Po proteins truncated in their cytoplasmic domains are not adhesive (Wong, M.H., and M.T. Filbin, 1994. J. Cell Biol. 126:1089-1097). To determine if the presence of these truncated forms of Po could have an effect on the functioning of the full-length Po, we coexpressed both molecules in CHO cells. The adhesiveness of CHO cells expressing both full-length Po and truncated Po was then compared to cells expressing only full-length Po. In these coexpressors, both the full-length and the truncated Po proteins were glycosylated. They reached the surface of the cell in approximately equal amounts as shown by an ELISA and surface labeling, followed by immunoprecipitation. Furthermore, the amount of full-length Po at the cell surface was equivalent to other cell lines expressing only full-length Po that we had already shown to be adhesive. Therefore, there should be sufficient levels of full-length Po at the surface of these coexpressors to measure adhesion of Po. However, as assessed by an aggregation assay, the coexpressors were not adhesive. By 60 min they had not formed large aggregates and were indistinguishable from the control transfected cells not expressing Po. In contrast, in the same time, the cells expressing only the full-length Po had formed large aggregates. This indicates that the truncated forms of Po have a dominant-negative effect on the adhesiveness of the full-length Po. Furthermore, from cross-linking studies, full-length Po, when expressed alone but not when coexpressed with truncated Po, appears to cluster in the membrane. We suggest that truncated Po exerts its dominant-negative effect by preventing clustering of full-length Po. We also show that colchicine, which disrupts microtubules, prevents adhesion of cells expressing only the full-length Po. This strengthens our suggestion that an interaction of Po with the cytoskeleton, either directly or indirectly, is required for adhesion to take place.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8830780      PMCID: PMC2120993          DOI: 10.1083/jcb.134.6.1531

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  57 in total

1.  Overexpression of cadherins and underexpression of beta-catenin inhibit dorsal mesoderm induction in early Xenopus embryos.

Authors:  J Heasman; A Crawford; K Goldstone; P Garner-Hamrick; B Gumbiner; P McCrea; C Kintner; C Y Noro; C Wylie
Journal:  Cell       Date:  1994-12-02       Impact factor: 41.582

Review 2.  Charcot-Marie-Tooth disease: a new paradigm for the mechanism of inherited disease.

Authors:  P I Patel; J R Lupski
Journal:  Trends Genet       Date:  1994-04       Impact factor: 11.639

3.  CHO cell aggregation induced by fibronectin-coated beads. Differences between wild-type and adhesion-variant cells.

Authors:  E Cheung; R L Juliano
Journal:  Exp Cell Res       Date:  1984-05       Impact factor: 3.905

Review 4.  Molecular genetics of Charcot-Marie-Tooth disease and related neuropathies.

Authors:  P F Chance; K H Fischbeck
Journal:  Hum Mol Genet       Date:  1994       Impact factor: 6.150

5.  Disruption of integrin function and induction of tyrosine phosphorylation by the autonomously expressed beta 1 integrin cytoplasmic domain.

Authors:  M E Lukashev; D Sheppard; R Pytela
Journal:  J Biol Chem       Date:  1994-07-15       Impact factor: 5.157

6.  Integrin beta 1 cytoplasmic domain dominant negative effects revealed by lysophosphatidic acid treatment.

Authors:  L Smilenov; R Briesewitz; E E Marcantonio
Journal:  Mol Biol Cell       Date:  1994-11       Impact factor: 4.138

7.  Effect of microtubule-destroying drugs on the spreading and shape of cultured epithelial cells.

Authors:  L V Domnina; J A Rovensky; J M Vasiliev; I M Gelfand
Journal:  J Cell Sci       Date:  1985-03       Impact factor: 5.285

8.  Expression of beta 1B integrin isoform in CHO cells results in a dominant negative effect on cell adhesion and motility.

Authors:  F Balzac; S F Retta; A Albini; A Melchiorri; V E Koteliansky; M Geuna; L Silengo; G Tarone
Journal:  J Cell Biol       Date:  1994-10       Impact factor: 10.539

9.  The cytoplasmic domain of the myelin P0 protein influences the adhesive interactions of its extracellular domain.

Authors:  M H Wong; M T Filbin
Journal:  J Cell Biol       Date:  1994-08       Impact factor: 10.539

10.  Embryonic axis induction by the armadillo repeat domain of beta-catenin: evidence for intracellular signaling.

Authors:  N Funayama; F Fagotto; P McCrea; B M Gumbiner
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

View more
  20 in total

Review 1.  Myelin P0: new knowledge and new roles.

Authors:  Joseph Eichberg
Journal:  Neurochem Res       Date:  2002-11       Impact factor: 3.996

2.  Immune deficiency in mouse models for inherited peripheral neuropathies leads to improved myelin maintenance.

Authors:  C D Schmid; M Stienekemeier; S Oehen; F Bootz; J Zielasek; R Gold; K V Toyka; M Schachner; R Martini
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

Review 3.  Features and functions of oligodendrocytes and myelin proteins of lower vertebrate species.

Authors:  Gunnar Jeserich; Katrin Klempahn; Melanie Pfeiffer
Journal:  J Mol Neurosci       Date:  2008-02-26       Impact factor: 3.444

4.  A novel adhesion molecule in human breast cancer cells: voltage-gated Na+ channel beta1 subunit.

Authors:  Athina-Myrto Chioni; William J Brackenbury; Jeffrey D Calhoun; Lori L Isom; Mustafa B A Djamgoz
Journal:  Int J Biochem Cell Biol       Date:  2008-11-12       Impact factor: 5.085

5.  Curcumin treatment abrogates endoplasmic reticulum retention and aggregation-induced apoptosis associated with neuropathy-causing myelin protein zero-truncating mutants.

Authors:  Mehrdad Khajavi; Ken Inoue; Wojciech Wiszniewski; Tomoko Ohyama; G Jackson Snipes; James R Lupski
Journal:  Am J Hum Genet       Date:  2005-09-30       Impact factor: 11.025

6.  Cryo-EM, X-ray diffraction, and atomistic simulations reveal determinants for the formation of a supramolecular myelin-like proteolipid lattice.

Authors:  Salla Ruskamo; Oda C Krokengen; Julia Kowal; Tuomo Nieminen; Mari Lehtimäki; Arne Raasakka; Venkata P Dandey; Ilpo Vattulainen; Henning Stahlberg; Petri Kursula
Journal:  J Biol Chem       Date:  2020-04-07       Impact factor: 5.157

7.  Peripheral myelin protein 22 and protein zero: a novel association in peripheral nervous system myelin.

Authors:  D D'Urso; P Ehrhardt; H W Müller
Journal:  J Neurosci       Date:  1999-05-01       Impact factor: 6.167

Review 8.  Animal models for inherited peripheral neuropathies.

Authors:  R Martini
Journal:  J Anat       Date:  1997-10       Impact factor: 2.610

9.  Cellular characterization of MPZ mutations presenting with diverse clinical phenotypes.

Authors:  Yi-Chung Lee; Kon-Ping Lin; Ming-Hong Chang; Yi-Chu Liao; Ching-Piao Tsai; Kwong-Kum Liao; Bing-Wen Soong
Journal:  J Neurol       Date:  2010-05-12       Impact factor: 4.849

10.  Charcot-Marie-Tooth disease: a novel Tyr145Ser mutation in the myelin protein zero (MPZ, P0) gene causes different phenotypes in homozygous and heterozygous carriers within one family.

Authors:  Alejandro Leal; Corinna Berghoff; Martin Berghoff; Gerardo Del Valle; Carlos Contreras; Olga Montoya; Erick Hernández; Ramiro Barrantes; Ursula Schlötzer-Schrehardt; Bernhard Neundörfer; André Reis; Bernd Rautenstrauss; Dieter Heuss
Journal:  Neurogenetics       Date:  2003-07-05       Impact factor: 2.660

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.